TY - JOUR
T1 - Polycystic ovary syndrome and the new antiepileptic drugs
T2 - A systematic review
AU - Ortiz Salas, Paola Andrea
AU - Rodríguez, Jesús Hernán
AU - Florez, Silvia Juliana Bueno
AU - Suarez, Fabio Enrique
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/9
Y1 - 2022/9
N2 - Objective: To evaluate the presence of polycystic ovary syndrome (PCOS) in women of reproductive age with the use of antiepileptic drugs. Methods: A systematic literature review of observational analytical studies (cohort, cross-sectional and case-control), from January 1966 to January 2021 on PCOS in women of reproductive age with the use of the antiepileptics. The search covered the Cochrane, MEDLINE, Embase and LILACS databases. Inclusion criteria: Studies reporting the frequency of PCOS with the antiepileptic drugs in women of reproductive age. Exclusion criteria: studies that did not have categorically relevant measurements, those published as abstracts only, and studies of investigational treatment. Data extraction was performed based on the PECOT strategy, considering the method of intervention, methodological quality, and presence of PCOS with the antiepileptic drugs. Results: A total of 2043 references were obtained from which 22 articles were selected by title and abstract. Four articles met the inclusion criteria. No articles were found describing the risk of PCOS upon exposure to levetiracetam, felbamate, gabapentin, lacosamide, pregabalin, rufinamide, tiagabine, topiramate, vigabatrin, or zonisamide. Only articles related to oxcarbazepine and lamotrigine were found, in which the frequency of PCOS was like that found in women without epilepsy. Conclusions: The anticonvulsants are probably safer, but the risk of developing PCOS associated with the antiepileptics cannot be established, since there are insufficient studies.
AB - Objective: To evaluate the presence of polycystic ovary syndrome (PCOS) in women of reproductive age with the use of antiepileptic drugs. Methods: A systematic literature review of observational analytical studies (cohort, cross-sectional and case-control), from January 1966 to January 2021 on PCOS in women of reproductive age with the use of the antiepileptics. The search covered the Cochrane, MEDLINE, Embase and LILACS databases. Inclusion criteria: Studies reporting the frequency of PCOS with the antiepileptic drugs in women of reproductive age. Exclusion criteria: studies that did not have categorically relevant measurements, those published as abstracts only, and studies of investigational treatment. Data extraction was performed based on the PECOT strategy, considering the method of intervention, methodological quality, and presence of PCOS with the antiepileptic drugs. Results: A total of 2043 references were obtained from which 22 articles were selected by title and abstract. Four articles met the inclusion criteria. No articles were found describing the risk of PCOS upon exposure to levetiracetam, felbamate, gabapentin, lacosamide, pregabalin, rufinamide, tiagabine, topiramate, vigabatrin, or zonisamide. Only articles related to oxcarbazepine and lamotrigine were found, in which the frequency of PCOS was like that found in women without epilepsy. Conclusions: The anticonvulsants are probably safer, but the risk of developing PCOS associated with the antiepileptics cannot be established, since there are insufficient studies.
KW - Adverse effects
KW - Anticonvulsants
KW - Polycystic ovary syndrome
KW - Cross-Sectional Studies
KW - Humans
KW - Female
KW - Polycystic Ovary Syndrome/drug therapy
KW - Anticonvulsants/adverse effects
KW - Lamotrigine
KW - Levetiracetam
UR - http://www.scopus.com/inward/record.url?scp=85134335279&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2022.106968
DO - 10.1016/j.eplepsyres.2022.106968
M3 - Artículo
C2 - 35843017
AN - SCOPUS:85134335279
SN - 0920-1211
VL - 185
SP - 106968
JO - Epilepsy Research
JF - Epilepsy Research
M1 - 106968
ER -